BOSTON— A private laboratory in Marlborough was among those that received a shipment including small amounts of active anthrax spores mistakenly delivered by the U.S. Department of Defense, state health officials said Tuesday. One of the samples was sent to the IQuum lab owned by Roche Molecular in Marlborough, 25 miles west of Boston, state health officials...» Read More
Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.
After Medivation, I moved onto the Orexigen presentation. It's a company I profiled at when it had data on one of its fat-fighting drugs at last year's diabetes conference, so I wanted to check up on its progress.
A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.
Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.
In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).
While I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly saying something along the lines of, "Coming Soon: Effient (Prasugrel)."
When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.
This won't be much of an end-of-summer holiday weekend for the folks at Merck and Schering-Plough. That's because early Tuesday morning (5am ET) the detailed results of the so-called SEAS study will be presented at a scientific conference in Germany. This is the test of MRK and SGP's cholesterol drug Vytorin, which showed a higher incidence of cancer among the patients taking the pill.
In the current monster-sized issue of Vogue, my producer, Ruth, while killing time on the Delta shuttle on our way from New York to Boston for a shoot this week, uncovered a blogworthy story buried in the hundreds and hundreds and hundreds of pages of fashion ads. It represents a whole new idea in the world of direct-to-consumer (DTC) drug advertising.
Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals and Cell Genesys, much lower. After the closing bell Tuesday, Bristol-Myers Squibb and Pfizer had an announcement to make...
After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?
Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.
As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)
Shares of Genentech are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche. Analyst guestimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.
A photographer for the "New York Post" snapped this picture last night of a nattily dressed Sam Waksal returning to a halfway house in the Bronx after going on a little shopping trip.
It was my turn to man the CNBC Alerts Desk earlier today from 9am ET to 1 pm ET. I had finished blogging about the "Barron's bounce" Amylin Pharmaceuticals was getting, based on the speculative mention about it being a potential takeout target for Eli Lilly. Then, I look up at the screen and see AMLN is absolutely tanking...
Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.
The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.